Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Finch Therapeutics Group, Inc.
Finch Announces Delisting from Nasdaq and SEC Deregistration
October 21, 2024
From
Finch Therapeutics Group, Inc.
Via
GlobeNewswire
Tickers
FNCH
Finch Announces Reverse Stock Split of Common Stock
June 09, 2023
From
Finch Therapeutics Group, Inc.
Via
GlobeNewswire
Tickers
FNCH
Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
May 10, 2023
From
Finch Therapeutics Group, Inc.
Via
GlobeNewswire
Tickers
FNCH
Finch Therapeutics Announces Executive Leadership Transitions
April 25, 2023
From
Finch Therapeutics Group, Inc.
Via
GlobeNewswire
Tickers
FNCH
Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement
April 18, 2023
From
Finch Therapeutics Group, Inc.
Via
GlobeNewswire
Tickers
FNCH
Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
March 23, 2023
From
Finch Therapeutics Group, Inc.
Via
GlobeNewswire
Tickers
FNCH
Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets
January 24, 2023
From
Finch Therapeutics Group, Inc.
Via
GlobeNewswire
Tickers
FNCH
Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results
November 10, 2022
From
Finch Therapeutics Group, Inc.
Via
GlobeNewswire
Tickers
FNCH
Finch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx Conference
November 09, 2022
From
Finch Therapeutics Group, Inc.
Via
GlobeNewswire
Tickers
FNCH
Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile Infection
October 24, 2022
From
Finch Therapeutics Group, Inc.
Via
GlobeNewswire
Tickers
FNCH
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.